Comparison of once daily fluticasone propionate aqueous nasal spray with once daily budesonide reservoir powder device in patients with perennial rhinitis

Clinical and Experimental Allergy

Volumn 31, Issue 6, 2001, Pages 855-863

  Kivisaari, E ^a   Baker, R C ^b   Price, M J ^b   Richards, D H ^b  

^a Lääkärikeskus ITE ^*  (Finland)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Aqueous nasal spray; Budesonide; Device preference; Fluticasone propionate; Patient satisfaction; Perennial rhinitis

Indexed keywords

BUDESONIDE; FLUTICASONE PROPIONATE;

ADOLESCENT; ADULT; AEROSOL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG PREFERENCE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; PERENNIAL RHINITIS; POWDER; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SNEEZING; SYMPTOM;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CHILD; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PATIENT SATISFACTION; POWDERS; RHINITIS, ALLERGIC, PERENNIAL; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 0035723571     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2001.01097.x     Document Type: Article

References (28)

1. The human pharmacology of fluticasone propionate
2. Oral bioavallalYility of fiutieasone prcrpionate in healthy subjects
3. Systemic bioavallability of fiuticasone propionate administered as nasal drops and aqueous nasal spray formulations
4. Pharmacokinetics and bioavailability of intranasal fiutieasone in humans
5. Double-blind comparison of intranasal fluticasone propionate, 200 micrograms, once daily with 200 micrograms twice daily in the treatment of patients with severe seasonal allergic rhinitis to ragweed
6. Once daffy fluticasone propionate aqueous nasal spray controls symptoms of most patients with seasonal allergic thinitis
7. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis
8. A multicentre study to assess long-term use of fluticasone propionate aqueous nasal spray in comparison with beclomethasone dipropionate aqueous nasal spray in the treatment of perennial rhinitis
9. Flutieasone propionate aqueous nasal spray: A well-tolerated and effective treatment for children with perennial rhinitis
10. Once daily intranasal fiuticasone propionate is effective for perennial allergic rhinitis
11. Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis
12. A comparison of budesonide nasal dry powder with fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis
13. A comparison of aqueous suspensions of budesonide nasal spray (128 micrograms and 256 micrograms once daily) and fiuticasone propionate nasal spray (200 micrograms once daily) in the treatment of adult patients with seasonal allergic rhinitis
14. Inhaled fiuticasone propionate is a potent inhibitor of PAF-indaced cosinophil accumulation in guinna-pig lung
15. Inhaled flutieasone propionate. A review of its pharmacodynamie and pharmacokinetic properties, and therapeutic use in asthma
16. Clinical experience with fluticasone pmpionate in asthma: A meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less
17. A comparison of the efficacy and tolerance of aqueous beclomethasone nasal spray with the conventional pressurized spray
18. A single blind clinical comparison between 2 preparations of budesonide in the treatment of seasonal allergic rhinitis
19. Comparison of powder and aerosolized budesonide in perennial rhinitis: Validation of rhinitis quality of life questionnaire
20. Powder administration of pure budesonide for the treatment of seasonal allergic rhinitis
21. Deposition pattern from a nasal pump spray
22. Seintigraphic assessment of the oropharyngeal and nasal depositions of fusafungine from a pressurized inhaler and from a novel pump spray device
23. Nasal distribution of budesonide inhaled via a powder inhaler
24. Once daily fiuticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone dipropionate
25. A plaecbocontrolled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: Efficacy in allergic and non-allergic perennial rhinitis
26. A 1-year placebo-controlled study of intmnasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: A safety and biopsy study
27. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamie-pituitury-adrenal-axis activity
28. Long-term safety and efficacy of budesonide nasal aerosol in perennial rhinitis. A 12-month multiecntre study